SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

10 Nov 2022 Evaluate
The total revenue hovered 270.52% to Rs. 43.87 millions for the September 2022 quarter as against Rs. 11.84 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2022 is Rs. -89.33 millions as compared to Net Loss of Rs. -109.83 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 improved to -72.44% as compared to -97.99% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 43.87 11.84 270.52 79.26 31.90 148.46 118.44 134.78 -12.12
Other Income 2.06 5.03 -59.05 6.42 13.43 -52.20 53.17 77.54 -31.43
PBIDT -72.44 -97.99 -26.07 -138.74 -208.20 -33.36 -313.26 -227.93 37.44
Interest 0.69 1.50 -54.00 1.71 3.03 -43.56 5.30 8.15 -34.97
PBDT -73.13 -99.49 -26.50 -80.45 -174.07 -53.78 -318.56 -236.08 34.94
Depreciation 16.20 10.34 56.67 32.01 20.68 54.79 43.93 43.46 1.08
PBT -89.33 -109.83 -18.67 -112.46 -194.75 -42.25 -362.49 -279.54 29.67
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -53.23 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -53.23 0.00
PAT -89.33 -109.83 -18.67 -112.46 -194.75 -42.25 -362.49 -226.31 60.17
Equity 145.38 127.28 14.22 145.38 127.28 14.22 145.38 127.28 14.22
PBIDTM(%) -165.12 -827.62 -80.05 -175.04 -652.66 -73.18 -264.49 -169.11 56.40

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×